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Value of Cyfra 21-1 (C21) as determinant of survival, predictor of 
disease course and asssistant of therapeutic decisions in non-small-
cell lung cancer (NSCLC) patients (pts): a large 15-year study. 
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Melo, Maria J. 
Hospital Pulido Valente, Unidade De Oncologia Pneumológica, Lisboa, 
Portugal
To evaluate prognostic usefulness of C21 and, particularly to detect 
its value as early predictor of treatment results, NSCLC course and to 
decide neo-adjuvant or adjuvant CT in early stages, serum levels were 
measured during a 15-year period, in 2348 NSCLC pts and 376 pts 
with benign lung diseases. In 829 pts with early disease (I-IIIA) sub-
mitted to surgery (S), measurements of serum markers were performed 
immediately before S. Included in this group were 465 pts submitted to 
surgery alone (S), 276 to S plus adjuvant CT (SCT) and 88 to neo-adju-
vant CT (CTS). 
In all 1768 pts submitted to chemotherapy (CT) measurements were 
performed at the start of treatment; in 21.2% after 1st course in 65.5% 
after 2nd course and in 93.4% at the end of CT. In 798 pts, C21 was 
regularly monitored thereafter, each 2/3 months during all survival 
time. Overall more than 16000 C21 measurements were performed. 
Median values in benign diseases were signiﬁcantly lower than in 
NSCLC pts. Using cut-off value of 3.3 ng/ml with a speciﬁcity of 95%, 
overall sensitivity for NSCLC was 69.2 %. The percentage of higher 
than normal C21 values increase as staging advances (I - 29%; IV 
- 87%), so there is no place for C21 in early diagnosis. 
Baseline levels had a week although signiﬁcant relationships with 
response to CT (p=0.049). However % change at the end of 1st and 
2nd course of CT were more strongly related to survival and TTP than 
imaging assessment (p=0.00024 and p=0.0012, respectively). 
Signiﬁcant increases of C21 preceded evidence of disease progression 
in more than 95 % of NSCLC cases. Marginal( <2%) false-negative 
results allow us to take earlier therapeutic decision either to change CT 
treatment, to begin a more efﬁcient 2nd line treatment or even to stop 
aggressive therapy. Cox’s multivariate analysis identiﬁed C21 (among 
the 25 more frequently factors related to survival) as the strongest 
independent survival prognostic factor. 
Baseline levels above 3.3 ng/ml were related with a poor survival for 
all, including early stages. Patients with surgical stages but with high 
C21 values, submitted to S alone, present a disappointing median sur-
vival. This means that should be upper-staged and treated accordingly. 
Adjuvant and particularly neo-adjuvant CT treatment seems mandatory 
in these cases. In which concerns second-line CT the level of C21 at the 
beginning of treatment is also strongly related with the results obtained. 
The closed monitoring of C21 values allows a quick start of 2nd line 
CT and the results in terms of response and survival were signiﬁcantly 
related to this behaviour. 
Cyfra 21-1 is in conclusion, a strong prognostic factor for survival that 
should be considered a very important tool for staging, therapeutic 
decision, CT treatment’s evaluation and early detection changes in 
the course of disease. Thus C21 baseline values should be included 
in all randomized trials avoiding bias enrolment and allowing a more 
efﬁcient response evaluation. Signiﬁcant survival gains can be obtained 
with the correct usage of this highly speciﬁc, easily available and inex-
pensive method. 
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Analysis of EGFR gene copy number, EGFR mutations, KRAS 
mutations and EGFR expression in a cohort of non-small cell lung 
cancer patients treated with epidermal growth factor tyrosine 
kinase inhibitors at a North American institution.
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Background: Molecular proﬁling of tumours for tailored anti-can-
cer therapy promises improved efﬁcacy, morbidity minimization and 
optimal use of therapeutic resources by health care providers. The 
epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKI) Ge-
ﬁtinib (Iressa) and Erlotinib (Tarceva), a new class of targeted agents, 
are approved for the treatment of advanced non-small cell lung cancer 
(NSCLC). Unfortunately, only 8-15% of patients show an enhanced 
response to these drugs. Improved predictors of response and resistance 
to these agents are needed. It has been suggested that responders are 
identiﬁable by increased copy number of, or the presence of activat-
ing mutations in, the EGFR gene, whereas those exhibiting primary 
resistance carry mutually exclusive point mutations in the KRAS gene. 
We set out to investigate the correlation between clinical outcome and 
the presence or absence of these molecular markers in a population of 
patients treated with these agents at our institution.
Methods: Non-small cell lung cancer patients treated with Geﬁtinib 
and/or Erlotinib at the Tom Baker Cancer Centre (TBCC) between 
2002 and 2006 have been identiﬁed and included in the study. After the 
granting of ethical approval, diagnostic samples were obtained. EGFR 
protein expression has been performed by standard immunohistochem-
istry (IHC) techniques. Chromogenic In-Situ Hybridization (CISH - a 
variant of the FISH technique) is being performed. Genomic DNA is 
isolated from formalin-ﬁxed parafﬁn embedded samples and used in 
a nested PCR reaction to amplify exons of interest. Ampliﬁed exons 
are then directly sequenced using dye-terminator PCR and an Applied 
Biosystems 3130 genetic analyzer. EGFR gene copy number and pres-
ence or absence of mutations/deletions in the EGFR and KRAS genes 
are then correlated with patient response and outcome. 
Results: 65 patients, 45 treated with Geﬁtinib, 17 with Erlotinib as a 
ﬁrst EGFR TKI were included; another 3 patients were treated on the 
BR-21 protocol (Erlotinib vs. placebo) as a ﬁrst EGFR TKI and subse-
quently received Geﬁtinib after progressing. 40% of diagnostic samples 
are cytological and provide additional molecular analytical challenges. 
To date, about a third of cases have been assessed by DNA sequencing: 
2 EGFR exon 19 deletions out of 19 samples (5%) and 1 KRAS exon 2 
mutation out of 16 samples (6%) have been detected. EGFR IHC analy-
sis and CISH staining are currently underway. 
Conclusion: At the TBCC, in a select number of patients with ad-
vanced NSCLC, both EGFR TKI’s demonstrated clinical and radio-
logic anti-tumor activity with minimal side effects. The responders to 
both drugs at our institution were predominantly female, non-smoking 
Asians with adenocarcinoma. Detailed molecular analysis of NSCLC 
continues to pose challenges. The relationship between the presence 
or absence of these markers to each other and to patient outcome and 
speciﬁc demographic characteristics will be presented.
